Conversely, camizestrant has demonstrated clinical activity in patients with HR+/HER2− metastatic breast cancer with a variety of ESR1m, including Y537S, and reduces Y537S ESR1m levels in circulating tumor DNA (49). This evidence concerns the gene HR and neoplasm.